Table 3.
Patients | Airway | Alveoli | Interstitium | Vessel |
---|---|---|---|---|
Negative control patients | ||||
1 | Unremarkable | Emphysema, pigmented macrophages, focal organizing pneumonia | Mild interstitial fibrosis, carcinoid (micro)tumorlet | PH |
2 | Basement membrane fibrosis/small airway disease | Mild emphysema, bronchiolar metaplasia | Anthracosis, focal lymphoid aggregates, focal mild fibrosis | Unremarkable |
3 | Goblet cell hyperplasia | Emphysema, rare giant cells | Anthracosis | PH |
4 | Basement membrane fibrosis | Mild emphysema, edema, rare poorly formed granulomas with giant cells | Variably fibrotic with some severely fibrotic areas, foci of interstitial lymphoid infiltrate, anthracosis | PH, granuloma in vessel wall |
5 | Unremarkable | Mild emphysema | Anthracosis | Unremarkable |
COVID-19 survivors | ||||
6 | Unremarkable | Emphysema, atypical adenomatous hyperplasia, rare pigmented macrophages | Anthracosis | Unremarkable |
7a | Respiratory bronchiolitis | Emphysema, pigmented macrophages, Langerhans cell histiocytosis | Smoking-related interstitial fibrosis, scattered lymphoid aggregates | Unremarkable |
7b | Respiratory bronchiolitis, peribronchiolar fibrosis | Emphysema, pigmented macrophages, focal edema | Smoking-related interstitial fibrosis | Unremarkable |
8 | Mild peribronchiolar inflammation | Emphysema, focal poorly formed granulomas | Mild interstitial thickening, perivascular lymphoid aggregates | Unremarkable |
9 | Peribronchiolar fibrosis | Emphysema, with patchy chronic inflammation, focal edema | Patchy widened, smoking-related interstitial fibrosis | PH |
10 | Unremarkable | Mild emphysema | Mild interstitial fibrosis, anthracosis | PH |
11 | Basement membrane fibrosis | Emphysema, rare foamy macrophages | Rare foci of fibrosis, anthracosis | PH |
12 | Basement membrane fibrosis/small airway disease | Scattered poorly-formed granulomas and mild patchy inflammation | Poorly formed granulomas, anthracosis | PH |
13 | Mild small airway disease | Emphysema, scattered foamy macrophages | Unremarkable | PH |
14 | Unremarkable | Emphysema | Congestion, focal lymphoid infiltrate | Unremarkable |
15 | Peribronchial inflammation and fibrosis | Emphysema, rare organizing pneumonia | Mild interstitial inflammation, patchy fibrosis | Unremarkable |
16 | Unremarkable | Mild emphysema, edema, focal fibrin | Unremarkable | Unremarkable |
COVID-19 end-stage lung disease | ||||
17 | Submucosal lymphohistiocytic infiltrate | Intra-alveolar macrophages, collapse | Diffuse fibrosis (fibrotic DAD), focal changes suggestive of interstitial emphysema, patchy chronic inflammation, calcifications | Recanalized thrombi |
18 | Basement membrane fibrosis, submucosal lymphohistiocytic and eosinophilic inflammation, intraepithelial neutrophils suggestive of superimposed infection | Organizing pneumonia, collapse, abundant hemosiderin-laden macrophages, microcystic change with bronchiolar squamous metaplasia | Diffuse fibrosis (fibrotic DAD), moderate lymphocytic/mononuclear inflammation, pulmonary interstitial emphysema | Large recanalized thrombus |
19 | Postmortem sloughing of epithelium, submucosal edema, mild lymphocytic inflammation | Diffuse alveolar damage, mild hemorrhage, reactive pneumocytes | Mild but diffuse interstitial lymphocytic inflammation, edema | Focal perivascular edema |
DAD, diffuse alveolar damage; PH, pulmonary hypertension.